Gilead Completes $115‑per‑share Cash‑plus‑CVR Deal for Arcellx as Insider Exits Stake

TL;DR: Gilead Sciences closed its $115‑per‑share cash‑plus‑CVR tender offer for Arcellx on April 28, 2026, making the cell‑therapy firm a wholly owned subsidiary. An insider subsequently sold all his Arcellx shares and, after option and RSU cancellations, holds no remaining stake.

Context Gilead (NASDAQ: GILD) announced the deal in February 2026, offering $115 in cash plus a contingent value right (CVR) that could pay up to $5 per share if a regulatory milestone is met. Arcellx (NASDAQ: ACLX) traded around $88 before the offer, implying a premium of roughly 30%. The transaction values Arcellx at about $2.6 billion, a small fraction of Gilead’s market capitalization of roughly $410 billion. Biotech M&A premiums have averaged near 40% over the past two years, so this offer sits slightly below that benchmark.

Key Facts On April 28, 2026, Gilead’s subsidiary completed the tender offer, delivering $115 cash per share and one CVR per share to Arcellx shareholders. The merger closed the same day, turning Arcellx into a wholly owned subsidiary of Gilead. Following the merger, the reporting person tendered all his Arcellx shares; his unexercised options and RSUs were canceled under the merger terms, leaving him with no beneficial ownership in the company.

What It Means The CVR mechanism allows former Arcellx investors to benefit from future success without additional upfront cost, aligning incentives between Gilead and the acquired team. Canceling in‑the‑money options and RSUs converts those awards into immediate cash payments based on the $115 tender price, which explains why the insider no longer holds any stake. For Gilead, the deal adds a promising CAR‑T platform while limiting cash outflow to about $3.3 billion if all CVRs pay out, a modest slice of its annual R&D budget.

Watch for the milestone that triggers the CVR payments; if achieved, Gilead will disburse up to $5 per Arcellx share, potentially adding another $130 million to the total consideration.